Indexado en

Licencia y uso

Citaciones

Cited 1 times in

Altmetrics

Grant support

Funding for the UCREX Study was provided by Novartis Pharmaceuticals, Spain.

Análisis de autorías institucional

Compartir

Daily Clinical Practice in the Management of Chronic Urticaria in Spain: Results of the UCREX Study

Publicado en:Actas Dermo-Sifiliograficas. 113 (1): 4-14 - 2022-01-01 113(1), DOI: 10.1016/j.ad.2021.06.007

Autores: Puga, MF; Salvador, JFS; Tomas, JB; Gimenez-Arnau, A; Labrador-Horrillo, M; Miquel-Miquel, J; de Frutos, FJO; Dominguez, JS; Santiago, AV; Terradas-Montana, P; Vidal-Jorge, M; Presa, IJ

Afiliaciones

Resumen

Background: Chronic Urticaria (CU) is a debilitating disease whose treatment is mainly symptomatic. UCREX study aimed to identify CU patients' profile, disease management and quality-of-life (QoL) in daily clinical practice in Spain.& nbsp;Methods: Observational, 12-months prospective, multicenter study, included de novo or established CU patients attending to dermatology/allergy consultations in 39 Spanish hospitals. Main variables: Urticaria Activity Score (UAS), UAS over 7 days (UAS7). Secondary variables: CUQoL Questionnaire (CU-Q2oL), EuroQol-5 dimensions (EQ-5D), Medical Outcomes Study Sleep (MOS-Sleep) scale, Hospital Anxiety and Depression Scale (HADS).& nbsp;Results: 361 patients included. Of them, 176 (48.8%) considered for the main objective analysis. Mean age (SD) of 46.6 (14.2) years and 71.8% women. The year prior to inclusion, most patients (57.1%) were treated with non-sedating H1-antihistamines (NS-H1AH). At baseline, mean (SD) 3.6 (6.8) visits were registered to primary care. Mean (SD) UAS7 at baseline was 14.3 (11.0) and CU-Q2oL 24.1 (17.0) which tended to improve by 8.6 (9.7) and 13.9 (15.0), respectively, at 12-months. MOS-Sleep and EQ-5D remained steady during the study, except pain/discomfort and anxiety/depression which went from 58.7% and 49.6% to 29.6% and 26.9%, respectively. At baseline, HADS showed a mean (SD) anxiety of 8.7 (4.5) and depression 5.1 (4.4), decreasing to 7.0 (4.3) and 4.7 (4.3), respectively, at 12-months.& nbsp;Conclusions: Although most CU patients are treated with NS-H1AH, disease activity is still important, negatively affecting patients' QoL, work activity and healthcare resources use. An appropriate disease management could be the basis for symptoms control, QoL improvement and resources optimization.(C) 2022 Published by Elsevier Espana, S.L.U. on behalf of AEDV.& nbsp;

Palabras clave